Welcome to our dedicated page for Covalon Technologies news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on Covalon Technologies stock.
Covalon Technologies Ltd. reports company developments across advanced medical technologies for vascular access, infection prevention, wound care, and surgical consumables. Recurring updates describe clinical education, healthcare-conference activity, and product use around contamination of intravenous connections, healthcare-associated infection risk, skin integrity, and patient-care workflows.
Covalon news also includes fiscal results, management discussion and analysis availability, shareholder meeting matters, director compensation through deferred share units, and amendments to governance documents and incentive plans. Product-specific coverage includes solutions such as CovaClear IV Cover dressings and VALGuard Vascular Access Line Guard.
Covalon (OTCQX:CVALF) reported fiscal Q1 2026 results for the quarter ended December 31, 2025, with revenue $6.89M, gross margin 58.2%, adjusted EBITDA $426,829, and net income $125,377. Cash was approximately $17.9M after a $4.1M special dividend.
The company highlighted new customer additions, system-wide approval of VALGuard at a 300+ site IDN, a Vizient contract via HARTMANN USA, positive clinical validation reducing CLABSIs, and upcoming industry presentations and a Feb 25, 2026 webcast.
Covalon (OTCQX:CVALF) is sponsoring a continuing-education webinar on IV line contamination and CABSI prevention, presented by vascular access expert Dr. Nancy Moureau and hosted by the Association for Vascular Access (AVA).
The live session is scheduled for Tuesday, February 24, 2026 at 2:00 PM EST with a rebroadcast at 7:00 PM EST, and offers accredited continuing-education credit through AVA.
Covalon (OTCQX: CVALF) will release its Q1 Fiscal 2026 results on Wednesday, February 25, 2026, before markets open. A live conference call and webcast to discuss the results is scheduled for February 25, 2026 at 8:30am ET.
Investors can join via webcast or dial the North American toll-free number; a recording and filings will be available on the company website and SEDAR PLUS.
Covalon Technologies (OTCQX: CVALF) reported fiscal 2025 results for the year ended Sept 30, 2025, with FY revenue of $32.82M, up 5% year-over-year, and Q4 revenue of $8.69M, the company’s highest quarter of FY25.
The company reported FY net income of $2.06M, adjusted EBITDA of $3.71M, gross margin of 53% (56% excluding inventory write-offs), and recorded $715,983 in inventory provisions. Covalon paid its first-ever special dividend of $0.15 CAD per share, leaving cash of $17.0M and no debt as of Dec 5, 2025. Management named Katie Martinovich as CFO. Key commercial wins included a >50% Q4 increase in U.S. vascular access sales and a >$1M initial purchase order from a new U.S. partner for FY26 Q2 delivery.
Covalon Technologies (OTCQX: CVALF) will release its Q4 and year‑end Fiscal 2025 financial results on Thursday, December 11, 2025 before markets open. A conference call and live webcast to discuss results is scheduled for December 11, 2025 at 8:30 AM ET.
Investors can join the webcast at https://events.q4inc.com/attendee/516259946 or dial North American toll‑free 1‑800‑549‑8228 (Local Toronto 289‑819‑1520, Local New York 646‑564‑2877), Conference ID 57487. A recording and copies of the financial statements and MD&A will be available on www.covalon.com under Investors > News & Events and on SEDAR PLUS.
Covalon Technologies (OTCQX: CVALF) announced payment on November 18, 2025 of its first-ever special cash dividend of C$0.15 per common share, payable to shareholders of record as of November 4, 2025. The dividend follows several quarters of profitability and adoption of Covalon’s proprietary medical technologies.
Key financials cited: revenue +82% to $33.0 million, gross margin up from 41% to 56%, and Adjusted EBITDA flipped from -$7.8M to +$4.1M (trailing twelve months vs FY2022). The company cited its VALGuard clinical evidence study and a new CovaClear indication as growth drivers.
Covalon (OTCQX: CVALF, TSXV: COV) declared its first-ever special cash dividend totaling CAD 4,112,711.55 (CAD 0.15 per common share). The dividend is payable on November 18, 2025 to shareholders of record at the close of business on November 4, 2025. The Special Dividend is designated an eligible dividend for purposes of section 89 of the Income Tax Act (Canada).
The company reported a current cash balance of CAD 18.9 million, no debt, and profitability for the last six quarters. The Board stated it may or may not declare additional special dividends in the future. Shareholders do not need to act to receive the payment and are advised to consult financial advisors about tax treatment.
Covalon (OTCQX: CVALF) announced it will participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025, with CEO Brent Ashton in a fireside chat at 12:30 p.m. ET.
The session will highlight Covalon’s positioning as a microcap medical technologies company — including claims of profitability, a debt-free and cash-rich balance sheet, recent clinical and health-economic evidence supporting its products, and plans to use cash to accelerate shareholder value. The discussion will cover product validation, growth catalysts, and the company’s view on U.S. macro volatility.
Investors can register to attend in person or watch the presentation online; additional company information is available at www.covalon.com and on social media.
Covalon (OTCQX: CVALF) will exhibit at the ANCC National Magnet & Pathway Conference in Atlanta on October 8–10, 2025, where it will showcase products and new clinical evidence aimed at reducing CLABSIs, SSIs, and MARSIs.
Covalon will present peer‑reviewed VALGuard® Line Guard data from Children’s Hospital at Montefiore showing an association with reduced CLABSIs, including a sustained zero‑CLABSI period in a pediatric ICU, and will host authors at its booth #2535. VALGuard is indicated to cover IV connections but is not FDA cleared for infection prevention or CLABSI reduction.
Covalon Technologies (OTCQX: CVALF) announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference from September 25-27, 2025, in Providence, Rhode Island. The company will showcase its vascular access portfolio, highlighting recent clinical evidence and economic findings.
Key achievements include a peer-reviewed study showing 78% reduction in hospital-wide CLABSI rates using VALGuard® Line Guard at Children's Hospital at Montefiore. The company will present its product line including VALGuard® Line Guard, CovaClear® Dressings, IV Clear® Dressings, and SurgiClear®, designed to improve patient outcomes while providing cost savings for hospitals.